000300163 001__ 300163
000300163 005__ 20250518020537.0
000300163 0247_ $$2pmid$$apmid:40140136
000300163 0247_ $$2ISSN$$a0960-8923
000300163 0247_ $$2ISSN$$a1708-0428
000300163 0247_ $$2doi$$a DOI:10.1007/s11695-025-07829-1 
000300163 0247_ $$2doi$$aDOI:10.1007/s11695-025-07829-1
000300163 0247_ $$2altmetric$$aaltmetric:175684416
000300163 037__ $$aDKFZ-2025-00649
000300163 041__ $$aEnglish
000300163 082__ $$a610
000300163 1001_ $$0P:(DE-He78)79e2e48100b40ab9f33fb2cb119d6f07$$aBetzler, Johanna$$b0$$eFirst author$$udkfz
000300163 245__ $$aAntireflux Surgery in Patients with Moderate Obesity - Fundoplication or Roux-en-Y Gastric Bypass?
000300163 260__ $$aNew York, NY$$bSpringer$$c2025
000300163 3367_ $$2DRIVER$$aarticle
000300163 3367_ $$2DataCite$$aOutput Types/Journal article
000300163 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747057027_33
000300163 3367_ $$2BibTeX$$aARTICLE
000300163 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300163 3367_ $$00$$2EndNote$$aJournal Article
000300163 500__ $$a#EA:B440# / 2025 May;35(5):1750-1760
000300163 520__ $$aGastroesophageal reflux disease (GERD), often associated with obesity, impairs quality of life and can lead to complications. This study compared Fundoplication and Roux-en-Y Gastric Bypass (RYGB) in patients with WHO (World Health Organization) class I and II obesity and refractory GERD.A single-center, retrospective study analyzed 93 patients (55 Fundoplication, 38 RYGB) with BMI < 40 kg/m2 who underwent surgery between January 2018 and September 2021. Preoperative characteristics, surgical outcomes, and postoperative results after three months and after one year were analyzed. Quality of life was assessed using Bariatric Quality of Life (BQL) and Quality of Life in Reflux and Dispepsia (QOLRAD) questionnaires. Propensity-score matching (PSM) was performed using the parameters age, BMI and gender.Patients who underwent RYGB had higher preoperative BMI (35.9 vs. 27.5 kg/m2, p < 0.0001) and more metabolic comorbidities. Patients who underwent Fundoplication experienced longer anesthesia (192.5 vs. 112 min, p < 0.0001), operation times (134 vs. 79 min, p < 0.0001), and hospital stays (4 vs. 3 days, p = 0.0003). Complication rates in general (p = 0.0154, after three months) and dysphagia rates in particular (p = 0.0036, after three months and p = 0.0147, after one year) were higher in the Fundoplication group. Preoperatively, patients undergoing RYGB reported poorer quality of life in BQL questionnaires (p = 0.0008). PSM showed less reflux regression in the Fundoplication group after three months (p = 0.0223).Despite higher preoperative BMI and comorbidities, patients undergoing RYGB had shorter operative times and hospital stays. The results suggest RYGB may be preferable for patients with refractory GERD and class I and II obesity, but further research on long-term outcomes is needed.
000300163 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000300163 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000300163 650_7 $$2Other$$aAntireflux surgery
000300163 650_7 $$2Other$$aFundoplication
000300163 650_7 $$2Other$$aGERD
000300163 650_7 $$2Other$$aModerate obesity
000300163 650_7 $$2Other$$aRYGB
000300163 7001_ $$aWiegand, Nina$$b1
000300163 7001_ $$aKantorez, Alexandra$$b2
000300163 7001_ $$aFinze, Alida$$b3
000300163 7001_ $$0P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e$$aSchölch, Sebastian$$b4$$udkfz
000300163 7001_ $$aReißfelder, Christoph$$b5
000300163 7001_ $$aOtto, Mirko$$b6
000300163 7001_ $$aBlank, Susanne$$b7
000300163 773__ $$0PERI:(DE-600)2087903-9$$aDOI:10.1007/s11695-025-07829-1$$n5$$p1750-1760$$tObesity surgery$$v35$$x0960-8923$$y2025
000300163 909CO $$ooai:inrepo02.dkfz.de:300163$$pVDB
000300163 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79e2e48100b40ab9f33fb2cb119d6f07$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300163 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000300163 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000300163 9141_ $$y2025
000300163 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-18$$wger
000300163 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-18$$wger
000300163 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-18$$wger
000300163 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bOBES SURG : 2022$$d2024-12-18
000300163 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000300163 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000300163 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000300163 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000300163 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000300163 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000300163 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000300163 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000300163 9201_ $$0I:(DE-He78)B440-20160331$$kB440$$lNWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle$$x0
000300163 9201_ $$0I:(DE-He78)A430-20160331$$kA430$$lNWG-KKE Translationale Chirurgische Onkologie$$x1
000300163 9200_ $$0I:(DE-He78)B440-20160331$$kB440$$lNWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle$$x0
000300163 980__ $$ajournal
000300163 980__ $$aVDB
000300163 980__ $$aI:(DE-He78)B440-20160331
000300163 980__ $$aI:(DE-He78)A430-20160331
000300163 980__ $$aUNRESTRICTED